Abstracts tagged "Biologics"

Abstract Number: 2346 • 2019 ACR/ARP Annual Meeting
Interstitial Lung Abnormalities in Rheumatoid Arthritis Patients: Identifying Associated Risk Factors
Karina Bonfiglioli¹, Márcio Sawamura ², Renato Nakagawa ³, Fábio Arimura ³, Diana Rangel ³, Cleonice Bueno ⁴, Ana Cristina de Medeiros Ribeiro ¹, Carlos Carvalho ³, Eloisa Bonfa ⁵, Ronaldo Kairalla ³ and Leticia Kawano-Dourado ⁶, ¹Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Sao Paulo, Brazil, ²Division of Radiology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Br, Sao Paulo, Sao Paulo, Brazil, ³Pulmonary Division, Heart Institute (InCor)- Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, Sao Paulo, Sao Paulo, Brazil, ⁴Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, Sao Paulo, Sao Paulo, Brazil, ⁵Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Sao Paulo, Brazil, ⁶University of Sao Paulo, Sao Paulo, Brazil
Background/Purpose: A wide spectrum of interstitial lung abnormalities (ILA) occurs in patients with rheumatoid arthritis (RA). This study characterized ILA in large single-center cohort, including…
Abstract Number: 1399 • 2019 ACR/ARP Annual Meeting
Evaluation of Effectiveness and Usage Patterns of Tofacitinib in Treatment of Rheumatoid Arthritis in Australia: An Analysis from the OPAL-QUMI Real World Dataset
Paul Bird¹, Geoffrey Littlejohn ², Belinda Butcher ³, Tegan Smith ⁴, Candida da Fonseca Pereira ⁵, David Witcombe ⁵ and Hedley Griffiths ⁶, ¹Optimus Research, Kogarah, New South Wales, Australia, ²Monash Rheumatology, Clayton, Victoria, Australia, ³WriteSource Medical Pty Ltd, Lane Cove, New South Wales, Australia, ⁴OPAL Rheumatology Ltd, Sydney, New South Wales, Australia, ⁵Pfizer Australia, Sydney, New South Wales, Australia, ⁶Barwon Rheumatology Service, Geelong, Victoria, Australia
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Limited data from large real-world patient populations exist to describe…
Abstract Number: 2371 • 2019 ACR/ARP Annual Meeting
Risk of Malignancies Across Biologic Classes in Rheumatoid Arthritis: Analysis of a National Claim Database
Raphaèle Seror¹, Alexandre Lafourcade ², yann De Rycke ², Bruno Fautrel ³, Xavier Mariette ⁴ and Florence Tubach ⁵, ¹Université Paris Sud, Hôpitaux Universitaires Paris-Sud, AP-HP, INSERM UMR 1184, Le Kremlin-Bicêtre, France, ²Biostatistics, Public Health and Medical Information department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France, Paris, France, ³Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France, ⁴Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, ⁵Pitié Salpétrière University-Hospital, Paris, Ile-de-France, France
Background/Purpose: Our objectives were to estimate and compare the incidence rate of malignancies associated with the different classes of biologics in RA patients.Methods: We conducted…
Abstract Number: 1476 • 2019 ACR/ARP Annual Meeting
Impact of Alternate Mechanism of Action Biologics and Tofacitinib on TNF-α Inhibitor Prescribing in Psoriatic Arthritis: Results from Annual National Patient Chart Audits
Lynn Price¹, Phil Pouliot ¹ and Lauren Schmitt ¹, ¹Spherix Global Insights, Exton, PA
Background/Purpose: TNF-α inhibitor therapy has long been the standard of care for adult patients diagnosed with moderate to severe psoriatic arthritis (PsA), though several new…
Abstract Number: 2372 • 2019 ACR/ARP Annual Meeting
Post-Approval Comparative Safety Study of Tofacitinib and Biologic DMARDs: Five‑Year Results from a US-based Rheumatoid Arthritis Registry
Joel Kremer¹, Clifton Bingham ², Laura Cappelli ², Jeffrey Greenberg ³, Jamie Geier ⁴, Ann Madsen ⁴, Connie Chen ⁴, Alina Onofrei ⁵, Christine Barr ⁵, Dimitrios Pappas ⁶, Heather Litman ⁵, Kimberly Dandreo ⁵, Andrea Shapiro ⁷, Carol Connell ⁸ and Arthur Kavanaugh ⁹, ¹Albany Medical College, Albany, NY, ²Johns Hopkins University, Baltimore, MD, ³Corrona, LLC; NYU School of Medicine, Waltham, MA, ⁴Pfizer Inc, New York, NY, ⁵Corrona, LLC, Waltham, MA, ⁶Columbia University, New York, NY, ⁷Pfizer Inc, Peapack, NJ, ⁸Pfizer Inc, Groton, CT, ⁹University of California, San Diego School of Medicine, La Jolla, CA
Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of RA. Real‑world data (RWD) complement clinical trial data in assessing long-term safety. We evaluated…
Abstract Number: 1498 • 2019 ACR/ARP Annual Meeting
A Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Secukinumab in US Biologic-Naive Patients with Active Psoriatic Arthritis and Psoriatic Skin Lesions
Tien Nguyen¹, Melvin Churchill ², Robert Levin ³, Guillermo Valenzuela ⁴, Joseph Merola ⁵, Alexis Ogdie ⁶, Ana-Maria Orbai ⁷, Jose Scher ⁸, Arthur Kavanaugh ⁹, Shital Agawane ¹⁰, Farid Kianifard ¹¹, Chauncy Rollins ¹¹ and Olivier Chambenoit ¹¹, ¹Department of Dermatology, University of California, Irvine, Irvine, CA, ²Arthritis Center of Nebraska, Lincoln, NE, ³Clinical Research of West Florida, Inc and University of South Florida, Clearwater/Tampa, FL, ⁴Integral Rheumatology & Immunology Specialists, Plantation, FL, ⁵Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ⁶Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁷Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, NY, ⁹University of California, San Diego School of Medicine, La Jolla, CA, ¹⁰Novartis Healthcare Pvt Ltd, Hyderabad, India, ¹¹Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis that often develops in patients (pts) with psoriasis. Secukinumab (SEC) inhibits IL-17A, a key inflammatory cytokine…
Abstract Number: 2377 • 2019 ACR/ARP Annual Meeting
Methotrexate Discontinuation and Dose Decreases After Therapy with Tocilizumab: Results from the Corrona Rheumatoid Arthritis Registry
Dimitrios Pappas¹, Taylor Blachley ², Steve Zlotnick ³, Jennie Best ³, Kelechi Emeanuru ² and Joel Kremer ⁴, ¹Columbia University, New York, NY, ²Corrona, LLC, Waltham, MA, ³Genentech, Inc., South San Francisco, CA, ⁴Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY
Background/Purpose: Methotrexate (MTX) is frequently prescribed with biologic disease-modifying antirheumatic drugs. Evidence has shown that tocilizumab (TCZ) monotherapy is effective in the treatment of patients…
Abstract Number: 1504 • 2019 ACR/ARP Annual Meeting
Subcutaneous Secukinumab 150 Mg Provides Rapid and Sustained Relief in Total and Nocturnal Back Pains, Morning Stiffness, and Fatigue in Patients with Active Ankylosing Spondylitis over 4 Years
Helena Marzo-Ortega¹, Corinne Miceli-Richard ², Sonja Gill ³, Marina Magrey ⁴, Paula Machado ⁵, Abhijit Shete ⁶, Jianyuan Wang ⁶, Susanne Rohrer ⁶ and Atul Deodhar ⁷, ¹NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, University of Leeds, Leeds, Leeds, United Kingdom, ²Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, ³412 – 3075 Hospital Gate, Oakville, Canada, ⁴Division of Rheumatology, The MetroHealth System and School of Medicine, Case Western Reserve University, Cleveland, OH, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Oregon Health & Science University, Portland, OR
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory condition. Pain, stiffness, and fatigue are reported as the most troubling symptoms by 70–80%, 20–40%, and 50–60%…
Abstract Number: 2399 • 2019 ACR/ARP Annual Meeting
Changes in the Initial Usage Pattern of Biologic Disease-modifying Antirheumatic Drugs in Rheumatic Diseases During the past Twelve Years: A Real-world Setting Analysis
Carlos Sánchez-Piedra¹, María Colazo ², Rosa Roselló ³, Cristina Campos ⁴, P. Vela ⁵, Cristina Bohorquez ⁶, Carolina Pérez-García ⁷, Manuel Pombo-Suarez ⁸, Carlos Fernández-López ⁹, Dolores Ruiz-Montesinos ¹⁰, Fernando Alonso ¹¹, Federico Diaz-Gonzalez ¹² and Juan Jesús Gómez-Reino ¹³, ¹Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ²Hospital de Burgos, Burgos, ³Hospital San Jorge, Huesca, ⁴Hospital General de Valencia, Valencia, ⁵Hospital General Universitario de Alicante, Alicante, Comunidad Valenciana, Spain, ⁶Universitary Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology department, Alcala de Henares, Spain, ⁷Rheumatology, Hospital del Mar, Barcelona, Catalonia, Spain, ⁸Unit Research, Spanish Society of Rheumatology, Madrid, Spain, ⁹Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain, ¹⁰Hospital Virgen Macarena, Sevilla, ¹¹Unidad Investigación SER, Madrid, Spain, ¹²Hospital de Canarias, Tenerife, ¹³Hospital de Santiago, Santiago de Compostela
Background/Purpose: During the past 15 years, advancements in the understanding of the safety and effectiveness, as well as the expanding access and availability of biologic…
Abstract Number: 1515 • 2019 ACR/ARP Annual Meeting
Infections in Patients with Active Radiographic Axial Spondyloarthritis Treated with Ixekizumab in 2 Phase 3 Clinical Trials
Marina Magrey¹, Victoria Navarro-Compán ², Sandra Garces ³, Xenofon Baraliakos ⁴, David Sandoval ³, Jeffrey Lisse ³, Silvia Santisteban ³, David Adams ³, Fangyi Zhao ³ and Robert Inman ⁵, ¹Division of Rheumatology, The MetroHealth System and School of Medicine, Case Western Reserve University, Cleveland, OH, ²University Hospital La Paz, IdiPaz, Madrid, Spain, ³Eli Lilly and Company, Indianapolis, IN, ⁴Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ⁵University of Toronto, University Health Network, Toronto, ON, Canada
Background/Purpose: Ixekizumab (IXE) is a high-affinity monoclonal antibody that selectively targets IL-17A. IL-17 inhibitors have shown efficacy for radiographic axial spondyloarthritis (r-axSpA), with IXE currently…
Abstract Number: 2505 • 2019 ACR/ARP Annual Meeting
Can Biologics “Prevent” the Development of Psoriatic Arthritis in Psoriasis Patients? Data from a Large University Hospital Cohort in Argentina
Luciano Fernando Lo Giudice¹, Maria Laura Acosta Felquer ¹, Luis Daniel Mazzuoccolo ², Maria Laura Galimberti ² and Enrique Soriano ³, ¹Hospital Italiano de Buenos Aires, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ²Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina., Buenos Aires, Buenos Aires, Argentina
Background/Purpose: As psoriasis (Pso) commonly precedes psoriatic arthritis (PsA), an important unanswered question is whether treatment of Pso might influence the development of PsA in…
Abstract Number: 1520 • 2019 ACR/ARP Annual Meeting
Long-Term Treatment Patterns of Biologics and Apremilast Among Patients with Moderate-to-Severe Plaque Psoriasis by Psoriatic Arthritis Status
Steven Feldman ¹, Jingchuan Zhang², Diane Martinez ³, Lorena Lopez-Gonzalez ³, Elizabeth Holt Marchlewicz ³, George Shrady ³, Alan Mendelsohn ⁴ and Yang zhao ⁵, ¹Wake Forest Baptist Health, Winston-Salem, NC, ²Sun Pharmaceutical Industries, Princeton, NJ, ³IBM Watson Health, Washington, DC, ⁴Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ⁵Sun Pharmaceutical Industries, Princeton
Background/Purpose: Long-term real-world treatment patterns of psoriasis patients are not well characterized, especially those with comorbid psoriatic arthritis (PsA). This study examined the treatment patterns…
Abstract Number: 2544 • 2019 ACR/ARP Annual Meeting
Results of the Open-label, Non-randomized 52-Week Study to Evaluate Treatment Holidays and Rebound Phenomenon After Treatment with Belimumab in Patients with SLE
Sang-Cheol Bae¹, Richard Dimelow ², Beulah Ji ³, Regina Kurrasch ⁴, Saima Muzaffar ⁵, Raj Punwaney ⁴, David Roth ⁴, Paul Stober ⁴, Yeong-Wook Song ⁶, Wendy Xie ⁴ and Fengchun Zhang ⁷, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ²GSK, Stevenage, United Kingdom, ³GSK, Uxbridge, Middlesex, United Kingdom, ⁴GSK, Collegeville, PA, ⁵GSK, Stevenage, Hertfordshire, ⁶Seoul National University Hospital, Seoul, Republic of Korea, ⁷Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (People's Republic)
Background/Purpose: Belimumab is approved as add-on therapy in active, autoantibody-positive SLE. Safety and efficacy up to 13 years has been reported in adults, but potential…
Abstract Number: L12 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: 16 Week Results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial in Patients with Prior Inadequate Response or Intolerance to 1 or 2 Tumor Necrosis Factor Inhibitors
Atul A. Deodhar¹, Denis Poddubnyy², Cesar Pacheco-Tena³, Carlo Salvarani⁴, Eric Lespessailles⁵, Proton Rahman⁶, Pentti Järvinen⁷, Juan Sanchez-Burson⁸, Karl Gaffney⁹, Eun Bong Lee¹⁰, Eswar Krishnan¹¹, Silvia Santisteban¹¹, Xiaoqi Li¹¹, Fangyi Zhao¹¹, Hilde Carlier¹¹ and John D. Reveille¹², ¹Oregon Health & Science University, Portland, Portland, OR, ²Rheumatology, Campus Benjamin Franklin Charité – Universitätsmedizin, Germany and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany, ³Facultad de Medicina, Universidad Autónoma de Chihuahua, Chihuahua, Mexico, ⁴Azienda USL-IRCCS di Reggio Emilia and Universita’ di Modena e Reggio Emilia, Reggio Emilia, Italy, ⁵Rheumatology, CHR Orléans and University of Orléans, Orléans, France, ⁶Medicine, Memorial University, St John's, NF, Canada, ⁷Rheumatology, Kiljava Medical Research, Hyvinkää, Finland, ⁸Hospital Infanta Luisa, Sevilla, Spain, ⁹Rheumatology, Norfolk and Norwich University Hospital NHS Foundation Trust and Norwich Medical School, University of East Anglia, Norwich, United Kingdom, ¹⁰Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ¹¹Eli Lilly and Company, Indianapolis, IN, ¹²Rheumatology, McGovern Medical School at the University of Texas Health Science Center at Houston, USA, Houston, TX
Background/Purpose: TNF inhibitors (TNFi) are recommended for patients with axial SpA (axSpA) who do not respond to or tolerate NSAIDs. Some patients are inadequate responders…
Abstract Number: 552 • 2018 ACR/ARHP Annual Meeting
Drug Tolerability and Discontinuation Reasons of 7 Biologics in 4466 Treatment Courses of Rheumatoid Arthritis -the Answer Cohort Study-
Kosuke Ebina¹, Makoto Hirao², Motomu Hashimoto³, Wataru Yamamoto⁴, Akira Onishi⁵, Toru Hirano⁶, Ryota Hara⁷, Masaki Katayama⁸, Shuzo Yoshida⁹, Koji Nagai⁹, Yonsu Son¹⁰, Hideki Amuro¹⁰, Kengo Akashi¹¹, Koichi Murata³, Kosaku Murakami¹², Keiichi Yamamoto¹³ and Hideki Yoshikawa¹⁴, ¹Orthopaedic Surgery, Osaka University Graduate School of Medicine, Suita, Japan, ²Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Suita, Japan, ³Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Department of Health Information Management, Kurashiki Sweet Hospital, Okayama, Japan, ⁵Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁶Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Suita, Japan, ⁷The Center for Rheumatic Diseases, Department of Orthopaedic Surgery, Nara Medical University, Kashihara, Japan, ⁸Department of Rheumatology, Osaka Red Cross Hospital, Osaka, Japan, ⁹Department of Internal Medicine (IV), Osaka Medical College, Osaka, Japan, ¹⁰First Department of Internal Medicine, Kansai Medical University, Osaka, Japan, ¹¹Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ¹²Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ¹³Department of Medical Statistics, Osaka City University, Osaka, Japan, ¹⁴Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, Suita Osaka, Japan
Background/Purpose: Drug tolerability indicates both the patient’s and doctor’s satisfaction and useful summary measure of overall treatment effectiveness and toxicity. Although more than 5 years…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].